Stockreport

Artiva Biotherapeutics (ARTV) Is Up 113.9% After FDA Fast Track for AlloNK in Refractory RA – Has the Bull Case Changed? [Yahoo! Finance]

Artiva Biotherapeutics, Inc.  (ARTV) 
PDF refractory rheumatoid arthritis in combination with rituximab, prioritizing this indication amid ongoing clinical trials across several autoimmune diseases. This marks [Read more]